Clinical trials: Teicoplanin
Pharmacokinetics, Amoxicillin-clavulanate
Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)
Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).
- Conditions
- Pharmacokinetics, Amoxicillin-clavulanate, Piperacillin-tazobactam, Meropenem
- Trial name
- PADECMO (NCT06426836)
- Testing
- Amoxicillin-clavulanate, Piperacillin-tazobactam, Meropenem
- Where
- 3 sites in Belgium
- Volunteers
- 300 people
- Sponsor
- University Hospital, Ghent
Pharmacokinetics, Amoxicillin-clavulanate
Antibiotic Dosing in Pediatric Intensive Care
Pharmacokinetics of antibiotics in critically ill neonates, infants and children
- Conditions
- Pharmacokinetics, Amoxicillin-clavulanate, Piperacillin-tazobactam, Vancomycin
- Trial name
- ADIC (NCT02456974)
- Testing
- blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care, blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care., blood sampling in patients receiving vancomycin as part of routine clinical care.
- Where
- Belgium
- Volunteers
- 640 people
- Sponsor
- University Hospital, Ghent
Comparison of Teicoplanin Used Three Times a Week in DSIs vs NDISs
Use of Teicoplanin on a Three-weekly Administration in the Infectious Diseases Unit
Teicoplanin is an antibiotic belonging to the class of glycopeptides, in use since 1986. Like its older "classmate" vancomycin, it inhibits protein synthesis by interfering with the synthesis of peptidoglycan, and is active on…
- Trial name
- 3-TEICO (NCT06426212)
- Testing
- Use of teicoplanin three times a week
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Ospedaliera di Lecco
Teicoplanin-based Antimicrobial Therapy, Staphylococcus Aureus
Teicoplanin-based Antimicrobial Therapy in Staphylococcus Aureus Bone and Joint Infection: Tolerance, Efficacy and Experience With Subcutaneous Administration
Staphylococci represent the first etiologic agents of bone and joint infection (BJI), leading glycopeptides use, especially in case of methicillin-resistance or betalactam intolerance.
- Conditions
- Teicoplanin-based Antimicrobial Therapy, Staphylococcus Aureus, Bone and Joint Infection
- Trial name
- NCT03177369
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Hospices Civils de Lyon